MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and mod...
Guardado en:
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7e740e1bfe9248e3844839c81b27bd6d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:7e740e1bfe9248e3844839c81b27bd6d |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:7e740e1bfe9248e3844839c81b27bd6d2021-11-18T11:09:06ZMG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants1664-322410.3389/fimmu.2021.778829https://doaj.org/article/7e740e1bfe9248e3844839c81b27bd6d2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.778829/fullhttps://doaj.org/toc/1664-3224Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and moderate infections. These therapeutics target the spike protein of SARS-CoV-2; however, emerging mutations in this protein reduce their efficiency. In this study, we developed a universal SARS-CoV-2 neutralizing antibody. We generated a humanized monoclonal antibody, MG1141A, against the receptor-binding domain of the spike protein through traditional mouse immunization. We confirmed that MG1141A could effectively neutralize live viruses, with an EC50 of 92 pM, and that it exhibited effective Fc-mediated functions. Additionally, it retained its neutralizing activity against the alpha (UK), beta (South Africa), and gamma (Brazil) variants of SARS-CoV-2. Taken together, our study contributes to the development of a novel antibody therapeutic approach, which can effectively combat emerging SARS-CoV-2 mutations.Sua LeeShina JangJihoon KangSoo Bin ParkYoung Woo HanHyemi NamMunkyung KimJeewon LeeKi Joon ChoJeonghun KimMiyoung OhJihye RyuJong Hyeon SeokYunhwa KimJee-Boong LeeMan-Seong ParkYong-Sung KimHosun ParkDong-Sik KimDong-Sik KimFrontiers Media S.A.articleMG1141ASARS-CoV-2monoclonal antibodyoutbreakspike proteinImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
MG1141A SARS-CoV-2 monoclonal antibody outbreak spike protein Immunologic diseases. Allergy RC581-607 |
spellingShingle |
MG1141A SARS-CoV-2 monoclonal antibody outbreak spike protein Immunologic diseases. Allergy RC581-607 Sua Lee Shina Jang Jihoon Kang Soo Bin Park Young Woo Han Hyemi Nam Munkyung Kim Jeewon Lee Ki Joon Cho Jeonghun Kim Miyoung Oh Jihye Ryu Jong Hyeon Seok Yunhwa Kim Jee-Boong Lee Man-Seong Park Yong-Sung Kim Hosun Park Dong-Sik Kim Dong-Sik Kim MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants |
description |
Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and moderate infections. These therapeutics target the spike protein of SARS-CoV-2; however, emerging mutations in this protein reduce their efficiency. In this study, we developed a universal SARS-CoV-2 neutralizing antibody. We generated a humanized monoclonal antibody, MG1141A, against the receptor-binding domain of the spike protein through traditional mouse immunization. We confirmed that MG1141A could effectively neutralize live viruses, with an EC50 of 92 pM, and that it exhibited effective Fc-mediated functions. Additionally, it retained its neutralizing activity against the alpha (UK), beta (South Africa), and gamma (Brazil) variants of SARS-CoV-2. Taken together, our study contributes to the development of a novel antibody therapeutic approach, which can effectively combat emerging SARS-CoV-2 mutations. |
format |
article |
author |
Sua Lee Shina Jang Jihoon Kang Soo Bin Park Young Woo Han Hyemi Nam Munkyung Kim Jeewon Lee Ki Joon Cho Jeonghun Kim Miyoung Oh Jihye Ryu Jong Hyeon Seok Yunhwa Kim Jee-Boong Lee Man-Seong Park Yong-Sung Kim Hosun Park Dong-Sik Kim Dong-Sik Kim |
author_facet |
Sua Lee Shina Jang Jihoon Kang Soo Bin Park Young Woo Han Hyemi Nam Munkyung Kim Jeewon Lee Ki Joon Cho Jeonghun Kim Miyoung Oh Jihye Ryu Jong Hyeon Seok Yunhwa Kim Jee-Boong Lee Man-Seong Park Yong-Sung Kim Hosun Park Dong-Sik Kim Dong-Sik Kim |
author_sort |
Sua Lee |
title |
MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants |
title_short |
MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants |
title_full |
MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants |
title_fullStr |
MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants |
title_full_unstemmed |
MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants |
title_sort |
mg1141a as a highly potent monoclonal neutralizing antibody against sars-cov-2 variants |
publisher |
Frontiers Media S.A. |
publishDate |
2021 |
url |
https://doaj.org/article/7e740e1bfe9248e3844839c81b27bd6d |
work_keys_str_mv |
AT sualee mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT shinajang mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT jihoonkang mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT soobinpark mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT youngwoohan mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT hyeminam mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT munkyungkim mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT jeewonlee mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT kijooncho mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT jeonghunkim mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT miyoungoh mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT jihyeryu mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT jonghyeonseok mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT yunhwakim mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT jeeboonglee mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT manseongpark mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT yongsungkim mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT hosunpark mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT dongsikkim mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants AT dongsikkim mg1141aasahighlypotentmonoclonalneutralizingantibodyagainstsarscov2variants |
_version_ |
1718420855123345408 |